AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39235772 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 37.5 mg daily for 8 weeks
Number of subjects: 40
Study 39235772 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for 8 weeks
Number of subjects: 40
Study 39235772 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 40
Study 39235772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 39235816 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty plus aggressive medical management (n=249)
Number of subjects: 512
Study 39235816 — intervention group
Group type: COMPARATOR
Intervention: Aggressive medical management alone (n=252)
Number of subjects: 512
Study 39235816 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty plus aggressive medical management
Number of subjects: 512
Study 39235816 — intervention group
Group type: COMPARATOR
Intervention: Aggressive medical management alone
Number of subjects: 512
Study 39235836 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Intervention (EMI) program designed to replace sitting time with physical activity for 6 weeks
Number of subjects: 39
Study 39235836 — intervention group
Group type: COMPARATOR
Intervention: Physical activity guidelines education (Control)
Number of subjects: 39
Study 39235836 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Intervention (EMI) program
Number of subjects: 39
Study 39235853 — intervention group
Group type: EXPERIMENTAL
Intervention: SteWARdS Antibiotic Defence app (intervention group)
Number of subjects: 348
Study 39235853 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 348
Study 39235855 — intervention group
Group type: EXPERIMENTAL
Intervention: POSTHOC app (digital SCP)
Number of subjects: 54
Study 39235855 — intervention group
Group type: COMPARATOR
Intervention: Usual care (paper-based SCP)
Number of subjects: 54
Study 39235870 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 39235931 — intervention group
Group type: EXPERIMENTAL
Intervention: Full DSME programme
Number of subjects: 120
Study 39235931 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% completion of DSME programme
Number of subjects: 120
Study 39235931 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% completion of DSME programme
Number of subjects: 120
Study 39235931 — intervention group
Group type: EXPERIMENTAL
Intervention: 0% completion of DSME programme (delayed education)
Number of subjects: 120
Study 39236047 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-mm introducer retraction before marker deployment
Number of subjects: 223
Study 39236047 — intervention group
Group type: COMPARATOR
Intervention: Standard marker placement
Number of subjects: 223
Study 39236052 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 20
Study 39236052 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 20
Study 39236052 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study 39236052 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall SMART DAPPER intervention
Number of subjects: 20
Study 39236057 — intervention group
Group type: EXPERIMENTAL
Intervention: ADFICE_IT clinical decision support system (CDSS) for deprescribing FRIDs
Number of subjects: 581
Study 39236057 — intervention group
Group type: EXPERIMENTAL
Intervention: Usability testing of the CDSS
Number of subjects: 581
Study 39236057 — intervention group
Group type: COMPARATOR
Intervention: Cluster-randomized controlled trial of the CDSS
Number of subjects: 581
Study 39236063 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of Activity in Situations-Heart Failure (FActS-HF15) questionnaire
Number of subjects: 185
Study 39236063 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention towards cardiac symptoms and symptom distress
Number of subjects: 185
Study 39236080 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-Led intervention
Number of subjects: 744
Study 39236080 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher fidelity
Number of subjects: 744
Study 39236080 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 744
Study 39236080 — intervention group
Group type: EXPERIMENTAL
Intervention: Researcher-Led intervention
Number of subjects: 744
Study 39236218 — intervention group
Group type: EXPERIMENTAL
Intervention: Evusheld
Number of subjects: 199
Study 39236218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 39236276 — intervention group
Group type: EXPERIMENTAL
Intervention: Inavolisib + Palbociclib + Letrozole
Number of subjects: 53
Study 39236276 — intervention group
Group type: EXPERIMENTAL
Intervention: Inavolisib + Palbociclib + Fulvestrant
Number of subjects: 53
Study 39236320 — intervention group
Group type: EXPERIMENTAL
Intervention: First-trimester Hb A 1C levels
Number of subjects: 1908
Study 39236320 — intervention group
Group type: COMPARATOR
Intervention: Psychiatric disorders prevalence
Number of subjects: 1908
Study 39236320 — intervention group
Group type: COMPARATOR
Intervention: Thyroid disorders prevalence
Number of subjects: 1908
Study 39236320 — intervention group
Group type: COMPARATOR
Intervention: Folic acid supplementation prevalence
Number of subjects: 1908
Study 39236727 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon angioplasty with the option of rescue stenting (DCB group)
Number of subjects: 2272
Study 39236727 — intervention group
Group type: COMPARATOR
Intervention: Intended deployment of second-generation thin-strut sirolimus-eluting stents (DES group)
Number of subjects: 2272
Study 39236729 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT-guided PCI
Number of subjects: 1604
Study 39236729 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 1604
Study 39236733 — intervention group
Group type: EXPERIMENTAL
Intervention: Casirivimab and imdevimab (150-1200 mg intravenously or 600-1200 mg subcutaneously) administered before or at the same time as mRNA-1273 vaccination
Number of subjects: 295
Study 39236733 — intervention group
Group type: COMPARATOR
Intervention: mRNA-1273 only
Number of subjects: 295
Study 39236733 — intervention group
Group type: EXPERIMENTAL
Intervention: Casirivimab and imdevimab plus mRNA-1273
Number of subjects: 295
Study 39236733 — intervention group
Group type: EXPERIMENTAL
Intervention: Casirivimab and imdevimab administered 48 mg and 12 mg intravenously
Number of subjects: 295
Study 39236733 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 administered 6 days before mAb
Number of subjects: 295
Study 39236736 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg infliximab
Number of subjects: 138
Study 39236736 — intervention group
Group type: COMPARATOR
Intervention: 5 mg/kg infliximab
Number of subjects: 138
Study 39236736 — intervention group
Group type: EXPERIMENTAL
Intervention: IIS (10 mg/kg infliximab)
Number of subjects: 138
Study 39236736 — intervention group
Group type: EXPERIMENTAL
Intervention: AIS (5 mg/kg infliximab, accelerated induction)
Number of subjects: 138
Study 39236736 — intervention group
Group type: EXPERIMENTAL
Intervention: SIS (5 mg/kg infliximab, standard induction)
Number of subjects: 138
Study 39236780 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate infusion
Number of subjects: 0
Study 39236780 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate clamp procedure
Number of subjects: 0
Study 39236781 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition360 intervention
Number of subjects: 31
Study 39236984 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotoxically dose-escalated chemoradiotherapy (60-74 Gy in 30-37 fractions)
Number of subjects: 172
Study 39236984 — intervention group
Group type: COMPARATOR
Intervention: PET-based selective nodal irradiation
Number of subjects: 172
Study 39237070 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial shunt treatment
Number of subjects: 665
Study 39237070 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 665
Study 39237070 — intervention group
Group type: EXPERIMENTAL
Intervention: Shunt treatment
Number of subjects: 665
Study 39237101 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertoli cells from Klinefelter syndrome (KS) patients cultured for 60 days in DMEM medium containing FBS
Number of subjects: 6
Study 39237101 — intervention group
Group type: COMPARATOR
Intervention: Sertoli cells from control (46,XY) patients cultured for 60 days in DMEM medium containing FBS
Number of subjects: 6
Study 39237101 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertoli cells from Klinefelter syndrome (KS) patients
Number of subjects: 6
Study 39237101 — intervention group
Group type: COMPARATOR
Intervention: Sertoli cells from control (46,XY) patients
Number of subjects: 6
Study 39237101 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional proteins and gene expressions (GDNF, BMP4, AR, CLDN11) in KS SCs
Number of subjects: 6
Study 39237101 — intervention group
Group type: COMPARATOR
Intervention: Functional proteins and gene expressions (GDNF, BMP4, AR, CLDN11) in control SCs
Number of subjects: 6
Study 39237135 — intervention group
Group type: EXPERIMENTAL
Intervention: Product A (iso-osmolar dose)
Number of subjects: 18
Study 39237135 — intervention group
Group type: EXPERIMENTAL
Intervention: Product B (iso-osmolar escalation dose)
Number of subjects: 18
Study 39237135 — intervention group
Group type: EXPERIMENTAL
Intervention: Product C (hypo-osmolar escalation dose)
Number of subjects: 18
Study 39237135 — intervention group
Group type: COMPARATOR
Intervention: Saline douche of matching osmolarity
Number of subjects: 18
Study 39237149 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior quadratus lumborum block
Number of subjects: 104
Study 39237149 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal morphine
Number of subjects: 104
Study 39237158 — intervention group
Group type: EXPERIMENTAL
Intervention: Gated 18F-fluorodeoxyglucose positron emission tomography coupled with computed tomography (FDG PET/CT)
Number of subjects: 84
Study 39237158 — intervention group
Group type: COMPARATOR
Intervention: Standard CT scan with intravenous contrast
Number of subjects: 84
Study 39237263 — intervention group
Group type: EXPERIMENTAL
Intervention: Training intervention
Number of subjects: 15
Study 39237263 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 15
Study 39237273 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital therapy programme using a smartphone application based on individual health data, duration of 180 days (90-day in-life phase followed by a 90-day follow-up phase).
Number of subjects: 0
Study 39237273 — intervention group
Group type: COMPARATOR
Intervention: Standard care for the treatment of primary arterial hypertension, duration of 180 days.
Number of subjects: 0
Study 39237276 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital tool for genetic cancer risk assessment
Number of subjects: 100
Study 39237276 — intervention group
Group type: COMPARATOR
Intervention: Usual care (clinician interview for genetic cancer risk assessment)
Number of subjects: 100
Study 39237277 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-assisted image analysis
Number of subjects: 500
Study 39237277 — intervention group
Group type: COMPARATOR
Intervention: Traditional diagnostic methods
Number of subjects: 500
Study 39237284 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperangulated VL
Number of subjects: 0
Study 39237284 — intervention group
Group type: COMPARATOR
Intervention: Macintosh VL (control group)
Number of subjects: 0
Study 39237283 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised intervention for announcing decisions of withholding or withdrawing life-sustaining treatments
Number of subjects: 538
Study 39237283 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 538
Study 39237321 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapropterin dihydrochloride (Kuvan®)
Number of subjects: 576
Study 39237427 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide 4 mg orally daily from days 1 to 21; Daratumumab 16 mg/kg intravenously on specified days; Dexamethasone 40 mg (age ≤ 75 years) or 20 mg (age > 75 years) orally on specified days.
Number of subjects: 112
Study 39237427 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide, Dexamethasone, Daratumumab
Number of subjects: 112
Study 39237545 — intervention group
Group type: EXPERIMENTAL
Intervention: Blastocyst-stage single embryo transfer
Number of subjects: 992
Study 39237545 — intervention group
Group type: COMPARATOR
Intervention: Cleavage-stage single embryo transfer
Number of subjects: 992
Study 39237725 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise prehabilitation plus nutritional guidance
Number of subjects: 204
Study 39237725 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 204
Study 39237725 — intervention group
Group type: EXPERIMENTAL
Intervention: Complier average causal effects for home-based exercise prehabilitation
Number of subjects: 204
Study 39237780 — intervention group
Group type: EXPERIMENTAL
Intervention: Effort Re-education Programme
Number of subjects: 170
Study 39237780 — intervention group
Group type: COMPARATOR
Intervention: Conventional Clinical Practice
Number of subjects: 170
Study 39237867 — intervention group
Group type: EXPERIMENTAL
Intervention: FASTRACS intervention (4 steps over 6 months)
Number of subjects: 420
Study 39237867 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control arm)
Number of subjects: 420
Study 39237867 — intervention group
Group type: EXPERIMENTAL
Intervention: FASTRACS intervention
Number of subjects: 420
Study 39237936 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person delivery of ECD parenting intervention
Number of subjects: 1200
Study 39237936 — intervention group
Group type: COMPARATOR
Intervention: Hybrid-delivery model (remote mHealth delivery via smartphones)
Number of subjects: 1200
Study 39238042 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face interview for CDR-SB
Number of subjects: 139
Study 39238042 — intervention group
Group type: COMPARATOR
Intervention: Medical record analysis for CDR-SB
Number of subjects: 139
Study 39238042 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face interview for 5-point scale CDR
Number of subjects: 139
Study 39238042 — intervention group
Group type: COMPARATOR
Intervention: Medical record analysis for 5-point scale CDR
Number of subjects: 139
Study 39238042 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis by domain of the CDR
Number of subjects: 139
Study 39238045 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemiarch repair (HAR)
Number of subjects: 0
Study 39238045 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended arch repair (EAR)
Number of subjects: 0
Study 39238045 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 39238045 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 39238051 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumothorax present after CPR
Number of subjects: 237
Study 39238051 — intervention group
Group type: EXPERIMENTAL
Intervention: History of obstructive lung disease
Number of subjects: 237
Study 39238051 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumothorax
Number of subjects: 237
Study 39238059 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated telehealth intervention (Motivational and Cognitive-Behavioral Management for Alcohol and Pain [INTV])
Number of subjects: 250
Study 39238059 — intervention group
Group type: COMPARATOR
Intervention: Control (CTL) condition
Number of subjects: 250
Study 39238103 — intervention group
Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation (iTBS)
Number of subjects: 60
Study 39238103 — intervention group
Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 60
Study 39238110 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40-60 mg once daily for 10 days
Number of subjects: 77
Study 39238110 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 77
Study 39238363 — intervention group
Group type: EXPERIMENTAL
Intervention: Health workers' perspectives on quality measures for improving QMNC, including effective training on healthy women/newborns management (n=2748, 66.3%), availability of informed consent job aids (n=2770, 66.9%), and effective training on women/newborns rights (n=2714, 65.5%)
Number of subjects: 4143
Study 39238363 — intervention group
Group type: EXPERIMENTAL
Intervention: QMNC index score (0-400) calculated as a synthetic measure
Number of subjects: 4143
Study 39238363 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience of care domain
Number of subjects: 4143
Study 39238363 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly linear decrease in QMNC index over time
Number of subjects: 4143
Study 39238363 — intervention group
Group type: EXPERIMENTAL
Intervention: HWs with <10 years of experience, HWs from public facilities, and midwives
Number of subjects: 4143
Study 39238363 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall HWs' perspectives on QMNC
Number of subjects: 4143
Study 39238363 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff censorship reported by HWs
Number of subjects: 4143
Study 39238934 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel social cognitive training
Number of subjects: 0
Study 39238934 — intervention group
Group type: COMPARATOR
Intervention: Modified problem-solving training
Number of subjects: 0
Study 39239186 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen (HFNO) therapy
Number of subjects: 160
Study 39239186 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 160
Study 39239277 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC) with docetaxel and cisplatin (TP) followed by radiation.
Number of subjects: 0
Study 39239277 — intervention group
Group type: EXPERIMENTAL
Intervention: TP plus PD-1 inhibition by pembrolizumab (MK-3475; 200 mg i.v. starting day 1 q3w for 17 cycles).
Number of subjects: 0
Study 39239277 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonresponders with ETSS < 30% or progressing disease).
Number of subjects: 0
Study 39239332 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography-guided transapical radiofrequency ablation (TARFACT)
Number of subjects: 5
Study 39239341 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 441
Study 39239341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study 39239905 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplex apolipoprotein panel using LC-MS/MS
Number of subjects: 23376
Study 39239939 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor human milk
Number of subjects: 2296
Study 39240359 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Number of subjects: 662
Study 39240498 — intervention group
Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel (axi-cel)
Number of subjects: 0
Study 39240498 — intervention group
Group type: COMPARATOR
Intervention: Tocilizumab and corticosteroids
Number of subjects: 0
Study 39240508 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobiliary radio-frequency ablation (EB-RFA) plus self-expandable metal stents (SEMS)
Number of subjects: 71
Study 39240508 — intervention group
Group type: COMPARATOR
Intervention: Self-expandable metal stents (SEMS) alone
Number of subjects: 71
Study 39240530 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost FE implant
Number of subjects: 1150
Study 39240530 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost SE implant
Number of subjects: 1150
Study 39240530 — intervention group
Group type: COMPARATOR
Intervention: Sham/timolol
Number of subjects: 1150
Study 39240530 — intervention group
Group type: EXPERIMENTAL
Intervention: SE implant
Number of subjects: 1150
Study 39240565 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel-aspirin
Number of subjects: 6100
Study 39240565 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 6100
Study 39240566 — intervention group
Group type: COMPARATOR
Intervention: Normal nicotine content (NNC) cigarettes only
Number of subjects: 326
Study 39240566 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low nicotine content (VLNC) cigarettes only
Number of subjects: 326
Study 39240566 — intervention group
Group type: EXPERIMENTAL
Intervention: VLNC cigarettes plus e-cigarettes with classic tobacco flavor (VLNC + TF)
Number of subjects: 326
Study 39240566 — intervention group
Group type: EXPERIMENTAL
Intervention: VLNC cigarettes plus e-cigarettes with preferred flavors (VLNC + PF)
Number of subjects: 326
Study 39240566 — intervention group
Group type: EXPERIMENTAL
Intervention: NNAL levels in VLNC + PF condition
Number of subjects: 326
Study 39240567 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (0.5 mg twice daily for 3 days, then 0.5 mg daily thereafter)
Number of subjects: 4432
Study 39240567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4432
Study 39240681 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART AMI-ACS smartphone app
Number of subjects: 0
Study 39241203 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 360 mg once every 3 weeks + nab-paclitaxel 125 mg/m² for four cycles
Number of subjects: 31
Study 39241203 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 360 mg once every 3 weeks + nab-paclitaxel 125 mg/m² for four cycles (including reTURBT)
Number of subjects: 31
Study 39241208 — intervention group
Group type: EXPERIMENTAL
Intervention: True electroacupuncture
Number of subjects: 239
Study 39241208 — intervention group
Group type: COMPARATOR
Intervention: Sham electroacupuncture
Number of subjects: 239
Study 39241211 — intervention group
Group type: EXPERIMENTAL
Intervention: Imlunestrant monotherapy (n = 114)
Number of subjects: 262
Study 39241211 — intervention group
Group type: EXPERIMENTAL
Intervention: Imlunestrant + abemaciclib (n = 42)
Number of subjects: 262
Study 39241211 — intervention group
Group type: EXPERIMENTAL
Intervention: Imlunestrant + abemaciclib + aromatase inhibitor (AI) (n = 43)
Number of subjects: 262
Study 39241211 — intervention group
Group type: EXPERIMENTAL
Intervention: Imlunestrant + everolimus (n = 42)
Number of subjects: 262
Study 39241211 — intervention group
Group type: EXPERIMENTAL
Intervention: Imlunestrant + alpelisib (n = 21)
Number of subjects: 262
Study 39241318 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA booster
Number of subjects: 50